Home Cart 0 Sign in  

[ CAS No. 39178-35-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 39178-35-3
Chemical Structure| 39178-35-3
Structure of 39178-35-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 39178-35-3 ]

Related Doc. of [ 39178-35-3 ]

Alternatived Products of [ 39178-35-3 ]

Product Details of [ 39178-35-3 ]

CAS No. :39178-35-3 MDL No. :MFCD00012830
Formula : C6H5Cl2NO Boiling Point : -
Linear Structure Formula :- InChI Key :BNTRVUUJBGBGLZ-UHFFFAOYSA-N
M.W : 178.02 Pubchem ID :12262826
Synonyms :

Calculated chemistry of [ 39178-35-3 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 41.39
TPSA : 29.96 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.89 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 2.1
Log Po/w (WLOGP) : 2.26
Log Po/w (MLOGP) : 0.73
Log Po/w (SILICOS-IT) : 1.87
Consensus Log Po/w : 1.39

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.64
Solubility : 0.403 mg/ml ; 0.00227 mol/l
Class : Soluble
Log S (Ali) : -2.36
Solubility : 0.778 mg/ml ; 0.00437 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.56
Solubility : 0.487 mg/ml ; 0.00274 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.15

Safety of [ 39178-35-3 ]

Signal Word:Danger Class:8
Precautionary Statements:P260-P261-P264-P270-P271-P280-P301+P312-P301+P330+P331-P302+P352-P303+P361+P353-P304+P340-P305+P351+P338-P310-P312-P321-P322-P330-P363-P405-P501 UN#:3261
Hazard Statements:H302-H312-H314-H332 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 39178-35-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 39178-35-3 ]
  • Downstream synthetic route of [ 39178-35-3 ]

[ 39178-35-3 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 67-56-1 ]
  • [ 39178-35-3 ]
  • [ 2459-09-8 ]
Reference: [1] Helvetica Chimica Acta, 1948, vol. 31, p. 571,574
  • 2
  • [ 39178-35-3 ]
  • [ 54-85-3 ]
Reference: [1] Pharm. Ind., 1952, vol. 14, p. 366
  • 3
  • [ 39178-35-3 ]
  • [ 69583-00-2 ]
Reference: [1] Zhurnal Obshchei Khimii, 1957, vol. 27, p. 72,75; engl. Ausg. S. 83, 85
  • 4
  • [ 39178-35-3 ]
  • [ 62-53-3 ]
  • [ 3034-31-9 ]
Reference: [1] Organic Letters, 2017, vol. 19, # 19, p. 5458 - 5461
[2] Journal of Chemical Research, Miniprint, 1986, # 1, p. 442 - 474
[3] Patent: WO2006/4195, 2006, A1, . Location in patent: Page/Page column 73; 132
  • 5
  • [ 55-22-1 ]
  • [ 39178-35-3 ]
Reference: [1] Journal of Materials Chemistry, 2011, vol. 21, # 24, p. 8574 - 8582
[2] Russian Journal of General Chemistry, 1994, vol. 64, # 12.2, p. 1809 - 1815[3] Zhurnal Obshchei Khimii, 1994, vol. 64, # 12, p. 2040 - 2047
[4] Molecules, 2001, vol. 6, # 1, p. 47 - 51
[5] RSC Advances, 2015, vol. 5, # 105, p. 86191 - 86198
[6] Journal of Medicinal Chemistry, 1995, vol. 38, # 1, p. 28 - 33
[7] Chemistry - A European Journal, 2010, vol. 16, # 20, p. 5961 - 5968
[8] Chemistry - A European Journal, 2006, vol. 12, # 4, p. 1097 - 1113
[9] Organometallics, 2015, vol. 34, # 11, p. 2543 - 2549
[10] Chemische Berichte, 1926, vol. 59, p. 1479,1482
[11] Journal of Organic Chemistry, 1982, vol. 47, # 13, p. 2633 - 2637
[12] Phosphorus and Sulfur and the Related Elements, 1981, vol. 11, p. 33 - 46
[13] Journal of Heterocyclic Chemistry, 1992, vol. 29, # 5, p. 1245 - 1273
[14] Acta Poloniae Pharmaceutica, 1993, vol. 50, # 2.3, p. 243 - 248
[15] Chemical and Pharmaceutical Bulletin, 1999, vol. 47, # 7, p. 1020 - 1023
[16] Russian Chemical Bulletin, 2001, vol. 50, # 3, p. 520 - 524
[17] Patent: WO2004/76450, 2004, A1, . Location in patent: Page 135
[18] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 2, p. 890 - 901
[19] Chemistry - A European Journal, 2010, vol. 16, # 7, p. 2258 - 2271
[20] Phosphorus, Sulfur and Silicon and the Related Elements, 2011, vol. 186, # 3, p. 552 - 557
[21] Synthetic Communications, 2012, vol. 42, # 17, p. 2555 - 2563
[22] MedChemComm, 2017, vol. 8, # 1, p. 152 - 157
[23] European Journal of Medicinal Chemistry, 2017, vol. 141, p. 362 - 372
  • 6
  • [ 14254-57-0 ]
  • [ 39178-35-3 ]
Reference: [1] Organic Process Research and Development, 2012, vol. 16, # 10, p. 1626 - 1634
  • 7
  • [ 37832-54-5 ]
  • [ 39178-35-3 ]
Reference: [1] Applied Organometallic Chemistry, 2015, vol. 29, # 1, p. 20 - 25
  • 8
  • [ 1496-40-8 ]
  • [ 39178-35-3 ]
  • [ 218156-96-8 ]
YieldReaction ConditionsOperation in experiment
86.3% With triethylamine In dichloromethane at 0℃; for 0.5 h; Isonicotinoyl chloride hydrochloride (6.48 g, 36.4 mmol, commercially available product) and triethylamine (5.57 ml, 54.6 mmol) were sequentially added at 0°C to a dichloromethane (10 ml) solution of 2-(1-piperidinyl)-5-(trifluoromethyl)aniline (4.45 g, 18.2 mmol) obtained as described in Referential Example 1-2B. The mixture was stirred for half an hour. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (200 g, hexane/ethyl acetate = 1/1) and recrystallization. Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl) phenyl]isonicotinamide (SRPIN-1, GIF-0340) (5.49 g, 86.3percent) was yielded as a colorless solid.
75% With triethylamine In dichloromethane at 0 - 20℃; for 3 h; A 25 mL round bottom flask initiallyplaced in an ice bath was charged with 0.629 g (3.389 mmol) ofisonicotinoyl chloride hydrochloride, 0.800 mL of triethylamine,8.00 mL of dichoromethane and 0.400 (1.64 mmol) of 2-(piperidin-1-yl)-5-(trifluoromethyl) aniline (8). The ice-bathwas removed andthe mixture was magnetically stirred at room temperature for 3 h.Then, 10.0 mL of distilled water was added, and the mixture wastransferred to a separatory funnel. The aqueous layer was extractedwith ethyl acetate (4 x 30.0 mL). The organic extracts were combinedand the resulting organic layer was washed with brine, driedover sodium sulphate, filtered, and concentrated under reducedpressure. The residue was purified by silica gel column chromatographyeluted with hexane-ethyl acetate (3:1 v/v). The solid wasfurther recrystallized with acetone. The compound SRPIN340 wasobtained as a white solid in 75percent yield (430 mg, 1.23 mmol).TLC Rf = 0.13 (hexane - ethyl acetate 3:1 v/v). mp 95.6-96.7 °C.IR (ATR, cm-1) νmax: 3347, 2945, 2917, 2811, 1679, 1611, 1587, 1556,1527, 1455, 1434, 1380, 1334, 1308, 1239, 1165, 1107, 1093, 1061,1022, 915, 895, 878, 839, 826, 751, 728, 681, 662, 644. 1H NMR(300 MHz, CDCl3) δ: 1.65-1.81 (m, 6H), 2.86 (t, 4H, J = 5.1 Hz), 7.28(d, 1H, J = 8.4 Hz), 7.37 (dd, 1H, J = 8.4 Hz and J = 1.8 Hz), 7.76 (dd,2H, J = 4.5 Hz and J = 1.5 Hz), 8.83-8.85 (m, 3H), 9.55 (s, 1H, NH).13C NMR (75 MHz, CDCl3) δ: 24.0, 27.1, 53.8, 116.6, 120.8, 121.1, 121.6(q, J C-F =3.7 Hz), 124.2 (q, J C-F = 270.5 Hz), 127.5 (q, J C-F = 32.3 Hz),133.4, 141.8, 145.9, 151.1, 163.0. HRMS (M + H+): Calculated forC18H19F3N3O, 350.1480; found: 350.1420.
33.9% With dmap; triethylamine In dichloromethane at 0 - 20℃; for 19.5 h; Isonicotinoyl chloride hydrochloride (151 mg, 0.850 mmol, commercially available product), triethylamine (450 μl, 3.23 mmol), and a catalytic amount of 4-(dimethylamino)pyridine were sequentially added at 0°C to a dichloromethane (5 ml) solution of 2-(1-piperidinyl)-5-(trifluoromethyl)aniline (173 mg, 0.708 mmol), obtained as described in Referential Example 1-2A. The resulting mixture was warmed to room temperature and stirred for 19.5 hours. Water was added to the mixture, and the resulting mixture was extracted three times with ethyl acetate. The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (10 g, hexane/ethyl acetate = 1.5/1) and recrystallization (hexane). Thus, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]isonicotinamide (SRPIN-1, code name GIF-0340) (83.8 mg, 0.240 mmol, 33.9percent) was yielded as a colorless solid. The melting point, and results of TLC and 1H NMR (CDCl3, 400 MHz), are as follows: m.p. 96-98°C; TLC Rf 0.40 (hexane/ethyl acetate = 1/1); 1H NMR (CDCl3, 400 MHz) δ 1.67-1.68 (m, 2H, CH2), 1.78 (tt, 4H, J = 5.5, 5.5 Hz, 2CH2), 2.88 (t, 4H, J = 5.5 Hz, 2CH2), 7.29 (d, 1H, J = 8.2 Hz, aromatic), 7.40 (dd, 1H, J = 1.8, 8.2 Hz, aromatic), 7.76 (dd, 2H, J = 2.0, 4.4 Hz, aromatic), 8.86 (dd, 2H, J = 2.0, 4.4 Hz, aromatic), 8.87 (d, 1H, J = 1.8 Hz, aromatic), 9.53 (s, 1H, NH).
Reference: [1] Patent: EP1712242, 2006, A1, . Location in patent: Page/Page column 18; 31
[2] European Journal of Medicinal Chemistry, 2017, vol. 134, p. 97 - 109
[3] Patent: EP1712242, 2006, A1, . Location in patent: Page/Page column 18; 30; 31
[4] Patent: EP2279750, 2011, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 39178-35-3 ]

Chlorides

Chemical Structure| 58757-38-3

[ 58757-38-3 ]

6-Chloronicotinoyl chloride

Similarity: 0.82

Chemical Structure| 1822-51-1

[ 1822-51-1 ]

4-(Chloromethyl)pyridine hydrochloride

Similarity: 0.75

Chemical Structure| 101990-73-2

[ 101990-73-2 ]

2-Chloro-4-(chloromethyl)pyridine

Similarity: 0.71

Chemical Structure| 23794-15-2

[ 23794-15-2 ]

1-(2-chloropyridine-4-yl)ethanone

Similarity: 0.71

Chemical Structure| 884495-38-9

[ 884495-38-9 ]

6-Chloro-4-methylnicotinaldehyde

Similarity: 0.70

Acyl Chlorides

Chemical Structure| 58757-38-3

[ 58757-38-3 ]

6-Chloronicotinoyl chloride

Similarity: 0.82

Chemical Structure| 39901-94-5

[ 39901-94-5 ]

Picolinoyl chloride hydrochloride

Similarity: 0.66

Chemical Structure| 1711-06-4

[ 1711-06-4 ]

3-Methylbenzoyl chloride

Similarity: 0.64

Chemical Structure| 1711-11-1

[ 1711-11-1 ]

3-Cyanobenzoyl chloride

Similarity: 0.58

Chemical Structure| 6068-72-0

[ 6068-72-0 ]

4-Cyanobenzoyl chloride

Similarity: 0.58

Related Parent Nucleus of
[ 39178-35-3 ]

Pyridines

Chemical Structure| 58757-38-3

[ 58757-38-3 ]

6-Chloronicotinoyl chloride

Similarity: 0.82

Chemical Structure| 872-85-5

[ 872-85-5 ]

4-Pyridinecarboxaldehyde

Similarity: 0.75

Chemical Structure| 1822-51-1

[ 1822-51-1 ]

4-(Chloromethyl)pyridine hydrochloride

Similarity: 0.75

Chemical Structure| 101990-73-2

[ 101990-73-2 ]

2-Chloro-4-(chloromethyl)pyridine

Similarity: 0.71

Chemical Structure| 23794-15-2

[ 23794-15-2 ]

1-(2-chloropyridine-4-yl)ethanone

Similarity: 0.71